Blood Stream Infections
1
Pipeline Programs
5
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
5 companies ranked by most advanced pipeline stage
Merck & Co.RAHWAY, NJ
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A
MSDIreland - Ballydine
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A1 trial
Active Trials
Sharp TherapeuticsPA - Pittsburgh
1 programClinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
bioMerieuxRapid Diagnostics
MSDClinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Clinical Trials (2)
Total enrollment: 2,350 patients across 2 trials
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
Start: Dec 2023Est. completion: Dec 20261,900 patients
Phase 4Recruiting
Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility
Start: Jan 2010Est. completion: Jan 2011450 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,350 patients
5 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.